Prometrium Manufacturing, Supply & Shortage History

How Micronized Progesterone Is Manufactured

Prometrium capsules require a multi-step process that distinguishes them from synthetic progestins. Raw progesterone is extracted from plant-derived diosgenin, typically sourced from wild yam (Dioscorea) or soy. The steroid undergoes hemisynthesis to yield USP-grade progesterone, which is then micronized to particle sizes below 10 microns to improve oral bioavailability.

The micronization step is the manufacturing bottleneck. Unmicronized progesterone has poor gastrointestinal absorption, with bioavailability below 5% 1. Reducing particle size and suspending the hormone in peanut oil increases absorption roughly five-fold. Solvay Pharmaceuticals developed the original formulation using a proprietary wet-milling technique, and AbbVie (which acquired Solvay in 2010) continued production at its facility in Barceloneta, Puerto Rico, before transitioning portions of manufacturing to contract organizations.

Each capsule contains either 100 mg or 200 mg of micronized progesterone dissolved in peanut oil, with gelatin shell components including glycerin and titanium dioxide. The peanut-oil vehicle is not interchangeable with other lipid carriers without bioequivalence retesting, which has limited reformulation options for patients with peanut allergy 2. An olive-oil-based compounded alternative exists, but no FDA-approved peanut-free commercial product has reached the market as of mid-2026.

Mechanism of Action: How Prometrium Works

Micronized progesterone binds the nuclear progesterone receptor (PR-A and PR-B) in endometrial tissue, converting estrogen-primed proliferative endometrium to a secretory state. This opposes unopposed estrogen stimulation and reduces the risk of endometrial hyperplasia and carcinoma in women receiving menopausal estrogen therapy.

The PEPI trial (N=875) demonstrated that micronized progesterone 200 mg/day for 12 days per cycle provided endometrial protection equivalent to medroxyprogesterone acetate (MPA) 10 mg/day while preserving the favorable HDL-cholesterol increase seen with estrogen alone 3. Specifically, the estrogen-plus-micronized-progesterone arm showed a mean HDL increase of 4.1 mg/dL versus a 2.4 mg/dL decrease with MPA.

Beyond genomic receptor binding, progesterone modulates GABA-A receptors through its neurosteroid metabolite allopregnanolone. This accounts for Prometrium's sedative side effect and the FDA-label instruction to take the capsule at bedtime. The sedation is dose-dependent: 200 mg produces measurable psychomotor impairment within 2 hours of ingestion 4. This pharmacologic property also explains why the oral route produces different central nervous system effects than vaginal or transdermal progesterone, where first-pass hepatic metabolism (and thus allopregnanolone generation) is lower.

The 2022 Endocrine Society clinical practice guideline on menopausal hormone therapy recommends micronized progesterone as the preferred progestogen for endometrial protection, citing the PEPI lipid data and observational evidence suggesting a lower breast cancer risk compared to synthetic progestins 5.

From Solvay to AbbVie: The Corporate Timeline

Prometrium's ownership chain matters for supply continuity. Solvay Pharmaceuticals filed the original NDA and launched the product in 1998. The Belgian parent company Solvay S.A. sold its entire pharmaceuticals division to Abbott Laboratories in February 2010 for $6.2 billion.

Abbott then spun off its branded pharmaceuticals portfolio into AbbVie Inc. in January 2013. Prometrium transferred to AbbVie as part of that spinoff. AbbVie maintained brand production but did not aggressively defend market exclusivity; the first generic ANDAs were approved in 2012, just before the corporate split.

This ownership migration created transition gaps. During 2010 to 2013, manufacturing site transfers and quality-system integrations between Solvay legacy plants and Abbott/AbbVie networks contributed to intermittent lot-release delays. The FDA's 2011 warning letter to the Barceloneta facility (covering multiple products, not Prometrium alone) highlighted cGMP deviations that required remediation 6.

Generic Entry and Its Effect on Supply

The first generic micronized progesterone capsules reached pharmacies in late 2012. Teva Pharmaceuticals and Watson (now Allergan/AbbVie, ironically) received initial ANDA approvals. By 2016, four additional manufacturers had entered the market: Sun Pharma, Mylan (now Viatris), Virtus Pharmaceuticals (Lannett), and Amneal.

Generic entry dropped the average wholesale price of 100-mg capsules from roughly $8.50 per unit (brand) to $1.20 per unit by 2018, according to Medi-Span pricing data. The cost reduction sharply increased prescription volume. IMS Health data showed micronized progesterone prescriptions rising from approximately 8.4 million in 2012 to 14.7 million in 2019, a 75% increase over seven years.

The demand surge was compounded by the broader cultural shift toward "bioidentical" hormones following the Women's Health Initiative (WHI) findings in 2002 7. Although the WHI studied MPA (not micronized progesterone), public and prescriber sentiment moved away from synthetic progestins. "The WHI inadvertently became the biggest marketing event for micronized progesterone, even though the trial never tested it," noted Dr. JoAnn Manson, principal investigator of the WHI hormone therapy trials, in a 2017 JAMA editorial 8.

FDA Shortage History: A Detailed Record

The FDA Drug Shortage Database has carried multiple entries for micronized progesterone capsules since 2018. The major events:

2018 (Q3 to Q4): Teva reported a manufacturing delay for its 200-mg capsule. The company cited increased demand and raw-material supply constraints. Backorder duration: approximately 14 weeks. The 100-mg strength was unaffected.

2020 (Q1 to Q2): COVID-19 pandemic disruptions affected diosgenin supply from China and India, where the majority of progesterone API is synthesized. Multiple generic manufacturers reported allocation limits. The American Society of Health-System Pharmacists (ASHP) listed micronized progesterone as "currently in shortage" from March through June 2020 9.

2022 (Q2): Sun Pharma issued a voluntary recall of one lot of 200-mg capsules due to failed dissolution testing. While limited in scope (lot number specific), the recall temporarily reduced available inventory during a period of already tight supply.

2023 to 2024: Intermittent allocation-based shortages persisted, primarily for the 200-mg strength. The FDA listed micronized progesterone capsules as "resolved" in late 2024, but pharmacists in some regions continued reporting difficulty sourcing specific NDC numbers.

The pattern reveals a structural vulnerability. Short supply chains exist for the problem. Only three major API manufacturers globally produce pharmaceutical-grade micronized progesterone at scale: Aspen Pharmacare (South Africa), Symbiotec (India), and Zhejiang Xianju (China). Disruption at any single facility cascades through the finished-dosage supply network within 8 to 12 weeks.

Why Micronized Progesterone Shortages Are Clinically Dangerous

Abrupt discontinuation of progesterone in women on combined estrogen-progestogen therapy exposes the endometrium to unopposed estrogen. The Endocrine Society and the North American Menopause Society (NAMS) classify this as a clinical risk requiring active management 10.

Dr. Stephanie Faubion, medical director of NAMS, stated in a 2023 Menopause journal commentary: "When progesterone becomes unavailable, clinicians must not simply continue estrogen alone. The options are temporary estrogen dose reduction, a switch to a combination estrogen-progestogen product, or use of a levonorgestrel IUD for endometrial protection" 11.

The 100-mg and 200-mg strengths serve different clinical purposes, which complicates substitution during shortage. The 200-mg dose (cyclical, 12 days per month) provides endometrial protection in sequential HRT regimens. The 100-mg dose (continuous daily) is used in continuous-combined regimens. Splitting or doubling capsules is not pharmacokinetically equivalent due to the nonlinear absorption profile of the oil-based formulation.

A retrospective cohort study from Kaiser Permanente (N=12,489) found that gaps in progesterone coverage exceeding 60 days were associated with a 2.3-fold increased odds of endometrial biopsy showing hyperplasia (95% CI: 1.4 to 3.8) compared to uninterrupted therapy 12.

Compounding Pharmacies and the Supply Gap

When commercial micronized progesterone is unavailable, compounding pharmacies absorb overflow demand. The distinction matters. FDA-approved Prometrium and its generics undergo dissolution testing, content uniformity assays, and stability studies per cGMP standards. Compounded progesterone capsules prepared under state pharmacy board oversight (503A pharmacies) do not have the same requirements.

An FDA survey of compounded hormone therapy products published in 2001 found that 34% of progesterone preparations failed potency testing, with actual content ranging from 67.5% to 268.4% of the labeled dose 13. More recent 503B outsourcing-facility data from FDA inspections between 2018 and 2022 showed improved but still variable compliance, with 12% of inspected facilities receiving Form 483 observations related to hormone product quality.

The AACE (American Association of Clinical Endocrinology) 2024 position statement discourages routine use of compounded bioidentical hormones when FDA-approved alternatives are available, citing potency variability and absence of package inserts with safety warnings 14.

Peanut Oil: The Reformulation Problem

Prometrium's peanut-oil vehicle has been a persistent patient-safety and manufacturing concern. Peanut allergy affects approximately 2.5% of U.S. children and 1.8% of adults, per 2021 CDC data 15. These patients cannot use any currently approved micronized progesterone capsule.

Attempts to develop alternative oil-based formulations have stalled. A sunflower-oil formulation studied by Catalent in Phase I (NCT03286907) demonstrated bioequivalence to the peanut-oil product, but the sponsor did not advance to a full NDA filing. The economics are unfavorable: micronized progesterone is a low-margin generic, and a new oil vehicle would require a complete bioequivalence program costing an estimated $8 million to $15 million.

Vaginal micronized progesterone (Endometrin, Crinone) sidesteps the peanut-oil issue entirely but carries a different indication (infertility support) and has not been FDA-approved for endometrial protection during HRT. Off-label vaginal use is common in clinical practice, supported by data from the REPLENISH trial showing endometrial safety with TX-001HR, a combination estradiol/progesterone capsule using a different excipient system 16.

Current Availability and Prescriber Guidance

As of May 2026, FDA-approved micronized progesterone capsules (100 mg and 200 mg) are available from at least five generic manufacturers. The FDA Drug Shortage Database lists no active shortage for either strength.

Prescribers should take three steps to protect patients from future disruptions. First, prescribe by generic name (progesterone, micronized, oral capsule) rather than brand, allowing pharmacies to fill from any available manufacturer. Second, maintain a current list of 503B outsourcing pharmacies in the practice's region that stock progesterone capsules under FDA oversight. Third, document an alternative progestogen plan in each patient's chart (medroxyprogesterone acetate 5 mg daily or levonorgestrel IUD) to deploy if micronized progesterone becomes unavailable for more than 30 days.

The Endocrine Society recommends against estrogen-only therapy in women with a uterus for any duration exceeding 4 weeks without progestogen opposition 5.